Immucell Stock Retained Earnings

ICCC Stock

USD 3.69 0.03 0.82%

ImmuCell fundamentals help investors to digest information that contributes to ImmuCell's financial success or failures. It also enables traders to predict the movement of ImmuCell Stock. The fundamental analysis module provides a way to measure ImmuCell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuCell stock.

	Last Reported	Projected for Next Year
Retained Earnings	-12 M	-11.4 M
Retained Earnings Total Equity	-3.3 M	-3.1 M

The current year's Retained Earnings is expected to grow to about (11.4 M). The current year's Retained Earnings Total Equity is expected to grow to about (3.1 M).

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ImmuCell Company Retained Earnings Analysis

ImmuCell's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Retained Earnings

Beginning RE + Income

-

Dividends

More About Retained Earnings | All Equity Analysis

Current ImmuCell Retained Earnings

(12.01 M)

Most of ImmuCell's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuCell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ImmuCell Retained Earnings Driver Correlations

Understanding the fundamental principles of building solid financial models for ImmuCell is extremely important. It helps to project a fair market value of ImmuCell Stock properly, considering its historical fundamentals such as Retained Earnings. Since ImmuCell's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ImmuCell's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ImmuCell's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.63	-0.61	0.95	0.94	0.66	0.82	0.38	0.61	0.9	0.96	0.95	0.58	0.83	-0.59	0.58	0.96	0.91	0.87	-0.92	0.8	0.77	0.78	0.82
Total Stockholder Equity	0.98		0.45	-0.46	0.92	0.85	0.77	0.7	0.45	0.61	0.9	0.9	0.94	0.42	0.8	-0.51	0.42	0.9	0.92	0.82	-0.92	0.77	0.7	0.77	0.75
Net Debt	0.63	0.45		-0.83	0.58	0.85	-0.02	0.84	-0.03	0.34	0.45	0.76	0.56	0.86	0.51	-0.57	0.86	0.74	0.46	0.65	-0.49	0.55	0.64	0.41	0.65
Retained Earnings	-0.61	-0.46	-0.83		-0.63	-0.78	-0.17	-0.85	0.14	-0.19	-0.53	-0.65	-0.58	-0.89	-0.65	0.67	-0.89	-0.64	-0.54	-0.75	0.42	-0.57	-0.87	-0.71	-0.87
Net Receivables	0.95	0.92	0.58	-0.63		0.89	0.65	0.78	0.27	0.56	0.85	0.89	0.9	0.53	0.78	-0.63	0.53	0.9	0.85	0.86	-0.83	0.72	0.81	0.84	0.84
Total Liab	0.94	0.85	0.85	-0.78	0.89		0.45	0.91	0.24	0.55	0.8	0.97	0.88	0.76	0.78	-0.65	0.76	0.96	0.81	0.87	-0.83	0.77	0.82	0.72	0.85
Total Current Assets	0.66	0.77	-0.02	-0.17	0.65	0.45		0.31	0.33	0.49	0.77	0.47	0.64	0.16	0.51	-0.1	0.16	0.47	0.75	0.48	-0.66	0.45	0.58	0.72	0.59
Short Term Debt	0.82	0.7	0.84	-0.85	0.78	0.91	0.31		0.11	0.32	0.71	0.86	0.84	0.75	0.82	-0.56	0.75	0.84	0.73	0.92	-0.68	0.86	0.8	0.68	0.84
Intangible Assets	0.38	0.45	-0.03	0.14	0.27	0.24	0.33	0.11		0.71	0.39	0.36	0.33	-0.19	0.32	-0.08	-0.19	0.39	0.43	0.17	-0.69	0.31	-0.06	0.01	-0.02
Accounts Payable	0.61	0.61	0.34	-0.19	0.56	0.55	0.49	0.32	0.71		0.52	0.55	0.43	0.31	0.25	-0.21	0.31	0.55	0.52	0.27	-0.81	0.25	0.31	0.26	0.31
Common Stock	0.9	0.9	0.45	-0.53	0.85	0.8	0.77	0.71	0.39	0.52		0.83	0.89	0.45	0.81	-0.54	0.45	0.83	0.99	0.8	-0.84	0.82	0.8	0.82	0.83
Long Term Debt	0.96	0.9	0.76	-0.65	0.89	0.97	0.47	0.86	0.36	0.55	0.83		0.91	0.62	0.81	-0.65	0.62	1.0	0.85	0.86	-0.87	0.8	0.73	0.68	0.77
Treasury Stock	0.95	0.94	0.56	-0.58	0.9	0.88	0.64	0.84	0.33	0.43	0.89	0.91		0.49	0.93	-0.51	0.49	0.91	0.91	0.95	-0.86	0.9	0.73	0.76	0.8
Property Plant Equipment	0.58	0.42	0.86	-0.89	0.53	0.76	0.16	0.75	-0.19	0.31	0.45	0.62	0.49		0.46	-0.54	1.0	0.58	0.44	0.6	-0.4	0.45	0.76	0.56	0.75
Current Deferred Revenue	0.83	0.8	0.51	-0.65	0.78	0.78	0.51	0.82	0.32	0.25	0.81	0.81	0.93	0.46		-0.57	0.46	0.82	0.84	0.95	-0.73	0.92	0.71	0.74	0.78
Short Term Investments	-0.59	-0.51	-0.57	0.67	-0.63	-0.65	-0.1	-0.56	-0.08	-0.21	-0.54	-0.65	-0.51	-0.54	-0.57		-0.54	-0.67	-0.56	-0.58	0.41	-0.47	-0.64	-0.61	-0.64
Net Tangible Assets	0.58	0.42	0.86	-0.89	0.53	0.76	0.16	0.75	-0.19	0.31	0.45	0.62	0.49	1.0	0.46	-0.54		0.58	0.43	0.6	-0.4	0.45	0.76	0.56	0.75
Long Term Debt Total	0.96	0.9	0.74	-0.64	0.9	0.96	0.47	0.84	0.39	0.55	0.83	1.0	0.91	0.58	0.82	-0.67	0.58		0.86	0.85	-0.88	0.8	0.72	0.68	0.76
Capital Surpluse	0.91	0.92	0.46	-0.54	0.85	0.81	0.75	0.73	0.43	0.52	0.99	0.85	0.91	0.44	0.84	-0.56	0.43	0.86		0.83	-0.86	0.84	0.79	0.81	0.82
Deferred Long Term Liab	0.87	0.82	0.65	-0.75	0.86	0.87	0.48	0.92	0.17	0.27	0.8	0.86	0.95	0.6	0.95	-0.58	0.6	0.85	0.83		-0.73	0.91	0.79	0.78	0.85
Long Term Investments	-0.92	-0.92	-0.49	0.42	-0.83	-0.83	-0.66	-0.68	-0.69	-0.81	-0.84	-0.87	-0.86	-0.4	-0.73	0.41	-0.4	-0.88	-0.86	-0.73		-0.73	-0.57	-0.57	-0.62
Short Long Term Debt	0.8	0.77	0.55	-0.57	0.72	0.77	0.45	0.86	0.31	0.25	0.82	0.8	0.9	0.45	0.92	-0.47	0.45	0.8	0.84	0.91	-0.73		0.64	0.62	0.71
Net Invested Capital	0.77	0.7	0.64	-0.87	0.81	0.82	0.58	0.8	-0.06	0.31	0.8	0.73	0.73	0.76	0.71	-0.64	0.76	0.72	0.79	0.79	-0.57	0.64		0.94	0.99
Net Working Capital	0.78	0.77	0.41	-0.71	0.84	0.72	0.72	0.68	0.01	0.26	0.82	0.68	0.76	0.56	0.74	-0.61	0.56	0.68	0.81	0.78	-0.57	0.62	0.94		0.95
Capital Stock	0.82	0.75	0.65	-0.87	0.84	0.85	0.59	0.84	-0.02	0.31	0.83	0.77	0.8	0.75	0.78	-0.64	0.75	0.76	0.82	0.85	-0.62	0.71	0.99	0.95

Click cells to compare fundamentals

Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.

Competition

Predict ImmuCell

Retained Earnings Over Time

Based on the latest financial disclosure, ImmuCell has a Retained Earnings of (12.01 Million). This is 101.29% lower than that of the Biotechnology sector and 112.39% lower than that of the Health Care industry. The retained earnings for all United States stocks is 100.13% higher than that of the company.

ImmuCell Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuCell's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics of similar companies.

ImmuCell is currently under evaluation in retained earnings category among its peers.

ImmuCell ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ImmuCell's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ImmuCell's managers, analysts, and investors.

Environmental

Governance

Social

ImmuCell Fundamentals

	Return On Equity	-0.16
	Return On Asset	-0.0487
	Profit Margin	(0.17) %
	Operating Margin	(0.25) %
	Current Valuation	44.61 M
	Shares Outstanding	8.91 M
	Shares Owned By Insiders	39.52 %
	Shares Owned By Institutions	14.51 %
	Number Of Shares Shorted	4.01 K
	Price To Earning	195.00 X
	Price To Book	1.25 X
	Price To Sales	1.42 X
	Revenue	17.47 M
	Gross Profit	7.65 B
	EBITDA	(2.5 M)
	Net Income	(5.77 M)
	Cash And Equivalents	11.04 M
	Cash Per Share	1.43 X
	Total Debt	16.69 M
	Debt To Equity	0.36 %
	Current Ratio	6.91 X
	Book Value Per Share	3.23 X
	Cash Flow From Operations	(4.67 M)
	Short Ratio	0.23 X
	Earnings Per Share	(0.49) X
	Target Price	14.0
	Number Of Employees	75
	Beta	0.57
	Market Capitalization	32.08 M
	Total Asset	43.81 M
	Retained Earnings	(12.01 M)
	Working Capital	10.92 M
	Current Asset	4.49 M
	Current Liabilities	258.78 K
	Net Asset	43.81 M

About ImmuCell Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:

How To Invest In ImmuCell

Details

Is ImmuCell Stock a good investment?

Details

What is ImmuCell's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out ImmuCell Piotroski F Score and ImmuCell Altman Z Score analysis.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(0.49)

Revenue Per Share

2.991

Quarterly Revenue Growth

0.549

Return On Assets

(0.05)

The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immucell Stock Retained Earnings

ImmuCell Company Retained Earnings Analysis

Retained Earnings

Beginning RE + Income

-

Dividends

Current ImmuCell Retained Earnings

ImmuCell Retained Earnings Driver Correlations

ImmuCell Retained Earnings Peer Comparison

ImmuCell ESG Sustainability

ImmuCell Fundamentals

About ImmuCell Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY